Brought to you by 
Private offering by AEterna Zentaris nets $14.1mm
22 Apr 2010
Executive Summary
AEterna Zentaris Inc., which is developing drug candidates for cancer, endocrine diseases, and benign prostatic hyperplasia, netted $14.1mm in a registered direct offering of 11.1mm shares at $1.35 (a 41% premium). Institutional investors also received five-year warrants to buy 4.4mm shares for $1.50. Rodman & Renshaw was the placement agent.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Private offering by AEterna Zentaris nets $14.1mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice